Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome

Fertil Steril. 2005 Dec;84(6):1755-7. doi: 10.1016/j.fertnstert.2005.06.028.


In women with polycystic ovary syndrome, chromium picolinate (200 microg/d) improves glucose tolerance compared with placebo but does not improve ovulatory frequency or hormonal parameters. This pilot study indicates that future studies in the polycystic ovary syndrome population should examine higher dosages or longer durations of treatment.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Female
  • Glucose Intolerance / drug therapy
  • Humans
  • Insulin Resistance*
  • Iron Chelating Agents / administration & dosage*
  • Menstrual Cycle / drug effects*
  • Ovary / physiology
  • Ovulation / drug effects
  • Picolinic Acids / administration & dosage*
  • Pilot Projects
  • Polycystic Ovary Syndrome / drug therapy*
  • Polycystic Ovary Syndrome / physiopathology


  • Iron Chelating Agents
  • Picolinic Acids
  • picolinic acid